ZYBERNO
Stock Report
Updated Aug 22, 2026

Xilio Therapeutics, Inc. (XLO)

Healthcare • NASDAQ

$9.23

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
34.0/100
WEAK BUSINESS
Xilio Therapeutics, Inc. (XLO) scores 34/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-118.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.16x)
Operating Margin (Operational Efficiency):CRITICAL (-48.9%)
Return on Capital (Capital Efficiency):CRITICAL (-129.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Xilio Therapeutics, Inc. (XLO) stock report — Zyberno Score 34/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, XLO generated -$57.13M in Owner Earnings. Capital was deployed as follows: $1.05M invested in capital expenditures. Reinvestment rate: 4.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:9.23
Market Cap:$54.62M

Valuation Multiples (3)

P/B Ratio:0.76x
P/S Ratio:0.85x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$75.12M

Price Action & Momentum (3)

Momentum Percentile:38 / 100
% of 52-Week High:72.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-33.6%
Reinvestment Rate:4.4%
Fundamental Growth Rate (g):-5.6%

Margin Analysis (3)

Operating Margin Ttm:-48.9%
Net Margin Ttm:-79.5%
Ebitda Margin:-45.5%

TTM Performance (2)

Operating Margin Ttm:-48.9%
Net Margin Ttm:-79.5%

Yield Metrics (2)

Earnings Yield:-$52.02
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-127.3%
Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.25x
Quick Ratio:4.25x
Cash Ratio:3.98x

Leverage Analysis (3)

Debt To Equity Ttm:0.16x
Debt-to-Equity Ratio:0.16x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:111,270,000.00
Cash And Cash Equivalents:136,040,000.00
Long Term Debt:$4.88M
Net Debt:-$129.74M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $64.09M
Linear Growth: 100.0%
📊 Click to view full XLO Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$31.37M

Bottom Line Performance (3)

-$50.94M
Income Before Tax:-$35.04M
Ebitda Ttm:-29,184,000.00

Operating Expenses (5)

Operating Expenses:95,460,000.00
R And D Expense:66,834,000.00
Sga Expense:28,626,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:357.6%
Sga To Revenue Percentage:153.1%
Ebitda Margin:-45.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$154.25M
Current Assets:$145.47M
Ppe Net:12,768,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:81,990,000.00
Current Liabilities:34,198,000.00
Long Term Debt:$4.88M
Short Term Debt:$1.43M

Equity & Capital (3)

Equity:$72.26M
Retained Earnings:-$434.69M
Common Stock:600,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:7,854,000.00

Special Items (2)

Contract Liabilities:35,318,000.00
Stock Based Compensation:1,598,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$56.31M-$57.37M

Investment Activities (2)

Investing Cash Flow:-$556.00K
Capital Expenditures Ttm:1,052,000.00

Financing Activities (3)

Financing Cash Flow:$35.71M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$3.33M

Non-Cash Items (1)

Depreciation Amortization Ttm:2,184,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.76
-$4.76
Earnings Per Share Ttm:-$8.61

Revenue & Cash Per Share (2)

Sales Per Share Ttm:10.83
Operating Cash Flow Per Share:-$0.84

Book Value & Capital (2)

Book Value Per Share:$12.21
Cash Per Share:22.99

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.42x
Working Capital Turnover Ttm:0.58x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:44.73
Cash Conversion Cycle:-2,042.73
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$57.13M

Damodaran Growth Analysis (2)

Reinvestment Rate:4.4%
Fundamental Growth Rate (g):-5.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-32.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:XLO
Company Name:Xilio Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:5.92M
Shares Outstanding Basic:19.40M
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-22 10:27:18 UTC
Data Timestamp:2026-08-20T09:23:14.619682
Scroll to Top